AKBA Bull Call Spread Strategy
AKBA (Akebia Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AKBA (Akebia Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $305.8M, a beta of 0.25 versus the broader market, a 52-week range of 0.823-4.079, average daily share volume of 4.4M, a public-listing history dating back to 2014, approximately 181 full-time employees. These structural characteristics shape how AKBA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.25 indicates AKBA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a bull call spread on AKBA?
A bull call spread buys an at-the-money call and sells an out-of-the-money call at a higher strike for defined risk and defined reward bounded by the strike width.
Current AKBA snapshot
As of June 30, 2026, spot at $1.13, ATM IV 327.90%, IV rank 65.37%, expected move 94.01%. The bull call spread on AKBA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this bull call spread structure on AKBA specifically: AKBA IV at 327.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 94.01% (roughly $1.06 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AKBA expiries trade a higher absolute premium for lower per-day decay. Position sizing on AKBA should anchor to the underlying notional of $1.13 per share and to the trader's directional view on AKBA stock.
AKBA bull call spread setup
The AKBA bull call spread below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AKBA near $1.13, the first option leg uses a $1.13 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AKBA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AKBA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.13 | N/A |
| Sell 1 | Call | $1.19 | N/A |
AKBA bull call spread risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-call strike plus net debit.
AKBA bull call spread payoff curve
Modeled P&L at expiration across a range of underlying prices for the bull call spread on AKBA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use bull call spread on AKBA
Bull call spreads on AKBA reduce the cost of a bullish AKBA stock position by selling a higher-strike call; suited to moderate-move theses where price reaches but does not vastly exceed the short strike.
AKBA thesis for this bull call spread
The market-implied 1-standard-deviation range for AKBA extends from approximately $0.07 on the downside to $2.19 on the upside. A AKBA bull call spread caps both the risk and the reward of a bullish position; relative to an outright long call on AKBA, the spread reduces the cost basis but limits the maximum profit to the strike width minus net debit. Current AKBA IV rank near 65.37% is mid-range against its 1-year distribution, so the IV signal is neutral; the bull call spread thesis on AKBA should anchor more to the directional view and the expected-move geometry. As a Healthcare name, AKBA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AKBA-specific events.
AKBA bull call spread positions are structurally moderately bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AKBA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AKBA alongside the broader basket even when AKBA-specific fundamentals are unchanged. Long-premium structures like a bull call spread on AKBA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current AKBA chain quotes before placing a trade.
Frequently asked questions
- What is a bull call spread on AKBA?
- A bull call spread on AKBA is the bull call spread strategy applied to AKBA (stock). The strategy is structurally moderately bullish: A bull call spread buys an at-the-money call and sells an out-of-the-money call at a higher strike for defined risk and defined reward bounded by the strike width. With AKBA stock trading near $1.13, the strikes shown on this page are snapped to the nearest listed AKBA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are AKBA bull call spread max profit and max loss calculated?
- Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-call strike plus net debit. For the AKBA bull call spread priced from the end-of-day chain at a 30-day expiry (ATM IV 327.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AKBA bull call spread?
- The breakeven for the AKBA bull call spread priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AKBA market-implied 1-standard-deviation expected move is approximately 94.01%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a bull call spread on AKBA?
- Bull call spreads on AKBA reduce the cost of a bullish AKBA stock position by selling a higher-strike call; suited to moderate-move theses where price reaches but does not vastly exceed the short strike.
- How does current AKBA implied volatility affect this bull call spread?
- AKBA ATM IV is at 327.90% with IV rank near 65.37%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.